title: High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies.
abstract: Prognostic impact of peripheral blood white blood cell count (WBC) at the diagnosis of childhood acute lymphoblastic leukaemia (ALL) was evaluated in a population-based consecutive series of 2666 children aged 1-15 treated for ALL between 1992 and 2008 in the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). Ten-year event-free (pEFS(10 y)) survival and overall (pOS(10 y)) survival were 0.75 ± 0.01 and 0.85 ± 0.01, respectively. Although treatment intensity was determined by WBC, non-remission and relapsed patients still had significantly higher WBC than those in remission for B-cell precursor (BCP) (median WBC: 24.8 vs. 14.0 vs. 8.3 × 10(9) /L, P < 0.001), but not for T-lineage (T-ALL) (median WBC: 127.8 vs. 113.0 vs. 86.8 × 10(9) /L, P = 0.22). pEFS was inversely related to WBC for BCP (P < 0.001), but not for T-ALL. WBC was not associated with risk of event for BCP or T-ALL for patients with minimal residual disease at the end of induction (MRD(d29) ) <10(-3). In contrast, for MRD(d29) ≥ 10(-3) and <5% leukaemic blasts in bone marrow at day 29, the pEFS(5 y) for WBC < 100.0 (N = 152) vs. ≥ 100.0 (N = 19) was 0.76 vs. 0.50 (P = 0.001). That was the case both for BCP (pEFS(5 y) 0.76 vs. 0.58) and for T-ALL (pEFS(5 y) 0.71 vs. 0.38). Whether the inferior EFS for the subset of patients with high WBC and slow initial response to treatment reflects rare or overlooked cytogenetic aberrations as well as the factors that determine WBC levels at diagnosis awaits exploration.
authors.affiliation: Centre for Paediatric Oncology and Haematology, University Childrens Hospital, Vilnius, Lithuania.
authors.forename: Goda
authors.initials: G
authors.lastname: Vaitkevičienė
authors.forename: Erik
authors.initials: E
authors.lastname: Forestier
authors.forename: Marit
authors.initials: M
authors.lastname: Hellebostad
authors.forename: Mats
authors.initials: M
authors.lastname: Heyman
authors.forename: Olafur G
authors.initials: OG
authors.lastname: Jonsson
authors.forename: Päivi M
authors.initials: PM
authors.lastname: Lähteenmäki
authors.forename: Susanne
authors.initials: S
authors.lastname: Rosthoej
authors.forename: Stefan
authors.initials: S
authors.lastname: Söderhäll
authors.forename: Kjeld
authors.initials: K
authors.lastname: Schmiegelow
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005387:Finland; D006801:Humans; D007055:Iceland; D007223:Infant; D007958:Leukocyte Count; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D016019:Survival Analysis